Zobrazeno 11 - 20
of 513
pro vyhledávání: '"Arthur Kavanaugh"'
Autor:
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 3, Pp 173-184 (2021)
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease
Externí odkaz:
https://doaj.org/article/619fc16b87424da49083d4b79c261367
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
The analysis of synovial tissue offers the potential for the comprehensive characterization of cell types involved in arthritis pathogenesis. The studies performed to date in synovial tissue have made it possible to define synovial pathotypes, which
Externí odkaz:
https://doaj.org/article/fb109d2c42f542379da47d9cb8d2e7c4
Autor:
Philip Mease, M. Elaine Husni, Soumya D. Chakravarty, Shelly Kafka, Dennis Parenti, Lilianne Kim, Kim Hung Lo, Elizabeth C. Hsia, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 11, Pp 640-647 (2020)
Objective To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis. Methods Patients were ra
Externí odkaz:
https://doaj.org/article/16791a817ad3468185cd6445bb00e287
Autor:
Brigitte Michelsen, Kristine Thomassen Berget, Jon Håvard Loge, Arthur Kavanaugh, Glenn Haugeberg
Publikováno v:
PLoS ONE, Vol 17, Iss 5, p e0266816 (2022)
ObjectiveKnowledge is needed on the total disease burden across the sexes in inflammatory arthritis (IA). We aimed to compare disease burden, including a broad range of health aspects, across men and women with IA treated with tumor necrosis factor i
Externí odkaz:
https://doaj.org/article/f6b33bcd62b440808b008d677a56c599
Autor:
Philip J. Mease, Dafna D. Gladman, Juan J. Gomez‐Reino, Stephen Hall, Arthur Kavanaugh, Eric Lespessailles, Georg Schett, Maria Paris, Nikolay Delev, Lichen Teng, Jürgen Wollenhaupt
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 8, Pp 459-470 (2020)
Objective Psoriatic arthritis (PsA) requires long‐term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long‐term Assessment of Clinical Efficacy (PALACE) 1, 2, a
Externí odkaz:
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Introduction Sleep disturbances, fatigue, and anxiety/depression in psoriatic arthritis (PsA) may be influenced by skin and musculoskeletal manifestations. All of these in turn affect the psychosocial impact of disease. The objective was to
Externí odkaz:
https://doaj.org/article/8760da30818045d795c8d5453d8b731c
Autor:
Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, Philippe Goupille, Tore K. Kvien, Marc deLongueville, Denis Mulleman, William J. Sandborn, Niels Vande Casteele
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 743-751 (2020)
Anti‐tumor necrosis factor (anti‐TNF) drugs are often prescribed for the treatment of rheumatoid arthritis (RA) and other immune‐mediated inflammatory diseases. Although this treatment has been shown to be effective in many patients, up to 40%
Externí odkaz:
https://doaj.org/article/c6c022374d9943c2b127a57924034b21
Autor:
Philip Mease, M. Elaine Husni, Shelly Kafka, Soumya D. Chakravarty, Diane D. Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Arthur Kavanaugh
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der Heijde score
Externí odkaz:
https://doaj.org/article/945104ccbdc445aca228892252650489
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Psoriatic arthritis (PsA) is an immune-mediated, clinically heterogeneous disease characterized by arthritis, enthesitis, dactylitis, spondylitis, and psoriasis of the skin and nails. Persistent articular inflammation in patients with PsA ca
Externí odkaz:
https://doaj.org/article/b03884f357c44bf8b4d4d381c264caf1
Autor:
Philip J. Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Juergen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, Shephard Mpofu, on behalf of the FUTURE 1 study group
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 1, Pp 18-25 (2020)
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326). Methods Following the 2‐year core trial, eligible patients receiving subcutaneous s
Externí odkaz:
https://doaj.org/article/27fe025cb3894ac286d6c0ed170ef04c